<DOC>
	<DOCNO>NCT01722786</DOCNO>
	<brief_summary>Patients treat Vitamin K antagonist ( VKA ) direct oral anticoagulant Rivaroxaban , Apixaban , Edoxaban Dabigatran , experience severe bleeding and/or need urgent interventions/operations wait include registry , emergency operation .</brief_summary>
	<brief_title>Reversal Agent Use Patients Treated With Direct Oral Anticoagulants Vitamin K Antagonists</brief_title>
	<detailed_description>The Registry offer opportunity evaluate effect reversal agent PCC , aPCC , rVIIa , specific antidots e.g . severe bleed patient treated oral anticoagulant . By collect case report several university hospital clinic , different treatment strategy clinical practice observe evaluate , may serve comprehensive information resource safe management DOA , also long-term anticoagulation base coumarin derivative near future . The current objective registry : 1 . Document clinical course outcome various clinical bleeding event associate DOA VKA patient severe life-threatening bleeding make intervention necessary 2 . Document clinical course outcome urgent surgical intervention within 24 hour admission patient DOA VKA treatment . 3 . Characterisation therapeutic strategy stop acute life-threatening bleed include follow agent method : 1. blood transfusion , 2. platelet concentrate 3. reversal agent [ e.g . vitamin K , prothrombin complex concentrate ( PCC ) , activate PCC ( aPCC ) , activate factor VII ( aVII ) , fibrinogen concentrate , fresh frozen plasma ( FFP ) ] 4. specific antidots , e.g . idarucizumab 5. haemodialysis 6. desmopressin 7. tranexamic acid 8. specific treatment respect mention treatment ( e.g . stop medication wait anticoagulant effect DOA decrease ) .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Patient Eligibility 1. ) Bleeding patient : Anticoagulated patient DOA VKA clinically overt major bleed accord specify ISTH definition nonsurgical patient : Symptomatic bleed critical area organ , intracranial , intraspinal , intraocular , retroperitoneal , intraarticular pericardial , intramuscular compartment syndrome Bleeding cause fall hemoglobin level 2 g L1 ( 1.24 mmol L1 ) lead transfusion two unit whole blood red cell . OR b ) Acute surgical need Patients treat DOA VKA need urgent operation wait ( &lt; 24 h last intake drug ) AND 2. without reversal agent use ( e.g . PCC , aPCC , rVIIa ) ( and/or haemodialysis dabigatran ) AND 3. provide informed consent acute event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>severe bleeding</keyword>
	<keyword>dabigatran</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>apixaban</keyword>
	<keyword>edoxaban</keyword>
	<keyword>PCC</keyword>
	<keyword>aPCC</keyword>
	<keyword>rVIIa</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>antidots</keyword>
	<keyword>idarucizumab</keyword>
</DOC>